Clinical Trial Update: A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial comparing Etentamig plus daratumumab versus daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multipl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Etentamig
• Lenalidomide (lenalidomide)

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 2, Phase 3 | Status: RECRUITING